Elite Pharmaceuticals (ELTP)
(Delayed Data from OTC)
$0.20 USD
0.00 (0.81%)
Updated Jul 19, 2024 03:59 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ELTP 0.20 0.00(0.81%)
Will ELTP be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ELTP based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ELTP
The Zacks Analyst Blog Highlights Danaher, Morgan Stanley, Pfizer, Elite Pharmaceuticals and Oil-Dri
Zacks Initiates Coverage of Elite Pharmaceuticals With Outperform Recommendation
ELTP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Elite Pharmaceuticals' (ELTP) FY24 Earnings Up, Gross Margin Down
Other News for ELTP
Treasure Hunt: 7 Penny Stocks Wall Street Hasn’t Discovered Yet
7 Strong Buy Penny Stocks to Buy Now: June 2024
Elite Pharmaceuticals announces FDA ANDA approval for generic methotrexate
Elite Pharmaceuticals Receives FDA Approval for Generic Methotrexate